117 related articles for article (PubMed ID: 11212772)
1. [Febrile neutropenia].
Masaoka T
Ryoikibetsu Shokogun Shirizu; 2000; (32):451-3. PubMed ID: 11212772
[No Abstract] [Full Text] [Related]
2. [Febrile neutropenia].
Tamura K
Rinsho Ketsueki; 2007 Apr; 48(4):273-84. PubMed ID: 17515117
[No Abstract] [Full Text] [Related]
3. [Problems and proposals for revision of the Japanese guideline for febrile neutropenia].
Yoshida M
Rinsho Ketsueki; 2011 Apr; 52(4):182-9. PubMed ID: 21566403
[No Abstract] [Full Text] [Related]
4. Drug therapy management of the febrile neutropenic cancer patient.
Finkbiner KL; Ernst TF
Cancer Pract; 1993; 1(4):295-304. PubMed ID: 8111439
[TBL] [Abstract][Full Text] [Related]
5. Use of myeloid growth factors for patients with febrile neutropenia: plus ca change, plus c'est la même chose.
Schiffer CA
Pediatr Blood Cancer; 2005 Sep; 45(3):242-3. PubMed ID: 15983983
[No Abstract] [Full Text] [Related]
6. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Hughes WT; Armstrong D; Bodey GP; Bow EJ; Brown AE; Calandra T; Feld R; Pizzo PA; Rolston KV; Shenep JL; Young LS
Clin Infect Dis; 2002 Mar; 34(6):730-51. PubMed ID: 11850858
[No Abstract] [Full Text] [Related]
7. The feasibility of early discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cordonnier C
Haematologica; 2006 Feb; 91(2):150a. PubMed ID: 16461296
[No Abstract] [Full Text] [Related]
8. Granulocyte-macrophage-colony-stimulating factor in established febrile neutropenia.
Mitchell PL; Pinkerton CR
J Clin Oncol; 1999 Sep; 17(9):3002. PubMed ID: 10561379
[No Abstract] [Full Text] [Related]
9. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary.
Masaoka T
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S49-52. PubMed ID: 15250021
[No Abstract] [Full Text] [Related]
10. [Empirical treatment of fever and neutropenia: rationalization of antimicrobial schemes in the patient with cancer].
Santos JI
Bol Med Hosp Infant Mex; 1989 Dec; 46(12):759-60. PubMed ID: 2627270
[No Abstract] [Full Text] [Related]
11. [Evidence-based management of neutropenia and fever].
Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan.
; ; ; ;
J Microbiol Immunol Infect; 2005 Dec; 38(6):455-7. PubMed ID: 16341349
[No Abstract] [Full Text] [Related]
15. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
16. Febrile neutropenia in haematological malignancies.
Sharma A; Lokeshwar N
J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
[TBL] [Abstract][Full Text] [Related]
17. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
18. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy.
de Pauw BE; Rubin RH
Transpl Infect Dis; 2006 Mar; 8(1):1-2. PubMed ID: 16623814
[No Abstract] [Full Text] [Related]
19. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
20. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
